Advanced Ovarian Cancer: Platinum resistant
A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)
Cancer Types: GYN, Ovarian
Lines of Therapy: 2nd Line Metastatic, 3rd Line+ Metastatic